Activation of farnesoid X receptor promotes triglycerides lowering by suppressing phospholipase A2 G12B expression

Molecular and Cellular Endocrinology

Volumn 436, Issue , 2016, Pages 93-101

  Liu, Qingli ^a   Yang, Meng ^a   Fu, Xuekun ^a   Liu, Renzhong ^a   Sun, Caijun ^b   Pan, Haobo ^a   Wong, Chi Wai ^c   Guan, Min ^a  

^a SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c NeuMed Pharmaceuticals Limited   (Hong Kong)

Author keywords

Farnesoid X receptor; Phospholipase A2 G12B; Triglyceride; Very low density lipoprotein

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HETERODIMER; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 G12B; SMALL HETERODIMER PARTNER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE; LIGAND; PHOSPHOLIPASE A2 GROUP X; PLA2G12B PROTEIN, HUMAN; PLA2G12B PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ENZYME REPRESSION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; LIPID DIET; LIPOGENESIS; LIPOPROTEIN SECRETION; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; AGONISTS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; HYPERLIPIDEMIA; KNOCKOUT MOUSE; LIPID METABOLISM; METABOLISM; PATHOLOGY; PROMOTER REGION;

ANIMALS; CHENODEOXYCHOLIC ACID; DIET, HIGH-FAT; GENE EXPRESSION REGULATION; GROUP X PHOSPHOLIPASES A2; HEP G2 CELLS; HUMANS; HYPERLIPIDEMIAS; ISOXAZOLES; LIGANDS; LIPID METABOLISM; LIPOPROTEINS, VLDL; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIGLYCERIDES;

EID: 84979691921     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2016.07.027     Document Type: Article

References (42)

1. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D.J., Suchy, F.J., Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276 (2001), 28857–28865.
2. Bavner, A., Sanyal, S., Gustafsson, J.A., Treuter, E., Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends Endocrinol. Metab. TEM 16 (2005), 478–488.
3. Bilz, S., Samuel, V., Morino, K., Savage, D., Choi, C.S., Shulman, G.I., Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290 (2006), E716–E722.
4. Boulias, K., Katrakili, N., Bamberg, K., Underhill, P., Greenfield, A., Talianidis, I., Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J. 24 (2005), 2624–2633.
5. Calkin, A.C., Tontonoz, P., Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nature reviews. Mol. Cell Biol. 13 (2012), 213–224.
6. Cariou, B., The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab. 34 (2008), 685–691.
7. Cave, M.C., Clair, H.B., Hardesty, J.E., Falkner, K.C., Feng, W., Clark, B.J., Sidey, J., Shi, H., Aqel, B.A., McClain, C.J., et al. Nuclear receptors and nonalcoholic fatty liver disease. Biochim. Biophys. Acta, 2016 Mar 4 pii: S1874-9399(16)30041-4.
8. Chen, F., Ma, L., Dawson, P.A., Sinal, C.J., Sehayek, E., Gonzalez, F.J., Breslow, J., Ananthanarayanan, M., Shneider, B.L., Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 278 (2003), 19909–19916.
9. Chiang, J.Y.L., Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha -hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 275 (2000), 10918–10924.
10. Cipriani, S., Mencarelli, A., Palladino, G., Fiorucci, S., FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. lipid Res. 51 (2010), 771–784.
11. Duran-Sandoval, D., Cariou, B., Percevault, F., Hennuyer, N., Grefhorst, A., van Dijk, T.H., Gonzalez, F.J., Fruchart, J.C., Kuipers, F., Staels, B., The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 280 (2005), 29971–29979.
12. Evans, M.J., Mahaney, P.E., Borges-Marcucci, L., Lai, K., Wang, S., Krueger, J.A., Gardell, S.J., Huard, C., Martinez, R., Vlasuk, G.P., et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009), G543–G552.
13. Fang, S., Suh, J.M., Reilly, S.M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21 (2015), 159–165.
14. Fiorucci, S., Cipriani, S., Baldelli, F., Mencarelli, A., Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog. lipid Res. 49 (2010), 171–185.
15. Guan, M., Qu, L., Tan, W., Chen, L., Wong, C.W., Hepatocyte nuclear factor-4 alpha regulates liver triglyceride metabolism in part through secreted phospholipase A(2) GXIIB. Hepatology 53 (2011), 458–466.
16. Hirokane, H., Nakahara, M., Tachibana, S., Shimizu, M., Sato, R., Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279 (2004), 45685–45692.
17. Iqbal, J., Boutjdir, M., Rudel, L.L., Hussain, M.M., Intestine-specific MTP and global ACAT2 deficiency lowers acute cholesterol absorption with chylomicrons and HDLs. J. lipid Res. 55 (2014), 2261–2275.
18. Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R.G., Krausz, K.W., Cai, J., Qi, Y., Fang, Z.Z., Takahashi, S., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Investig. 125 (2015), 386–402.
19. Li, X., Jiang, H., Qu, L., Yao, W., Cai, H., Chen, L., Peng, T., Hepatocyte nuclear factor 4alpha and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus. J. Virol. 88 (2014), 612–627.
20. Liu, W., Wong, C., Oleanolic acid is a selective farnesoid X receptor modulator. Phytotherapy research. PTR 24 (2010), 369–373.
21. Liu, Z., Law, W.-K., Wang, D., Nie, X., Sheng, D., Song, G., Guo, K., Wei, P., Ouyang, P., Wong, C.-W., et al. Synthesis and discovery of andrographolide derivatives as non-steroidal farnesoid X receptor (FXR) antagonists. RSC Adv. 4 (2014), 13533–13545.
22. Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., Loria, P., Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 47 (2015), 181–190.
23. Ma, K., Saha, P.K., Chan, L., Moore, D.D., Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Investig. 116 (2006), 1102–1109.
24. Mahdessian, H., Taxiarchis, A., Popov, S., Silveira, A., Franco-Cereceda, A., Hamsten, A., Eriksson, P., van't Hooft, F., TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 8913–8918.
25. Mencarelli, A., Fiorucci, S., FXR an emerging therapeutic target for the treatment of atherosclerosis. J. Cell. Mol. Med. 14 (2010), 79–92.
26. Mera, Y., Kawai, T., Ogawa, N., Odani, N., Sasase, T., Miyajima, K., Ohta, T., Kakutani, M., JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates lipid metabolism and attenuates atherosclerosis in hyperlipidemic animal models. J. Pharmacol. Sci. 129 (2015), 169–176.
27. Miller, N.E., Nestel, P.J., Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet 2 (1974), 929–931.
28. Nishigori, H., Tomura, H., Tonooka, N., Kanamori, M., Yamada, S., Sho, K., Inoue, I., Kikuchi, N., Onigata, K., Kojima, I., et al. Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 575–580.
29. Non-alcoholic Fatty Liver Disease Study, Group, Lonardo, A., Bellentani, S., Argo, C.K., Ballestri, S., Byrne, C.D., Caldwell, S.H., Cortez-Pinto, H., Grieco, A., Machado, M.V., et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig. Liver Dis. 47 (2015), 997–1006.
30. Porez, G., Prawitt, J., Gross, B., Staels, B., Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. lipid Res. 53 (2012), 1723–1737.
31. Raabe, M., Veniant, M.M., Sullivan, M.A., Zlot, C.H., Bjorkegren, J., Nielsen, L.B., Wong, J.S., Hamilton, R.L., Young, S.G., Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Investig. 103 (1999), 1287–1298.
32. Schoenfield, L.J., Lachin, J.M., Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann. Intern Med. 95 (1981), 257–282.
33. Song, P., Zhang, Y., Klaassen, C.D., Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicity in mice. Toxicol. Sci. Off. J. Soc. Toxicol. 123 (2011), 359–367.
34. Tao, H., Aakula, S., Abumrad, N.N., Hajri, T., Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor. Am. J. Physiol. Endocrinol. Metab. 298 (2010), E68–E79.
35. Trabelsi, M.S., Daoudi, M., Prawitt, J., Ducastel, S., Touche, V., Sayin, S.I., Perino, A., Brighton, C.A., Sebti, Y., Kluza, J., et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun., 6, 2015, 7629.
36. Wang, J., Fang, F., Huang, Z., Wang, Y., Wong, C., Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist. FEBS Lett. 583 (2009), 643–647.
37. Wang, S., Chen, Z., Lam, V., Han, J., Hassler, J., Finck, B.N., Davidson, N.O., Kaufman, R.J., IRE1alpha-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis. Cell Metab. 16 (2012), 473–486.
38. Watanabe, M., Houten, S.M., Wang, L., Moschetta, A., Mangelsdorf, D.J., Heyman, R.A., Moore, D.D., Auwerx, J., Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Investig. 113 (2004), 1408–1418.
39. Wiegman, C.H., Bandsma, R.H., Ouwens, M., van der Sluijs, F.H., Havinga, R., Boer, T., Reijngoud, D.J., Romijn, J.A., Kuipers, F., Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 52 (2003), 1081–1089.
40. Yamagata, K., Daitoku, H., Shimamoto, Y., Matsuzaki, H., Hirota, K., Ishida, J., Fukamizu, A., Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 279 (2004), 23158–23165.
41. Ye, J., Li, J.Z., Liu, Y., Li, X., Yang, T., Ma, X., Li, Q., Yao, Z., Li, P., Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. Cell Metab. 9 (2009), 177–190.
42. Zhang, Y., Lee, F.Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F.J., Willson, T.M., Edwards, P.A., Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 1006–1011.